Share

November 12, 2013; 81 (20) Article

Gray matter damage predicts the accumulation of disability 13 years later in MS

Massimo Filippi, Paolo Preziosa, Massimiliano Copetti, Gianna Riccitelli, Mark A. Horsfield, Vittorio Martinelli, Giancarlo Comi, Maria A. Rocca
First published October 11, 2013, DOI: https://doi.org/10.1212/01.wnl.0000435551.90824.d0
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
559

Share

Article Information

vol. 81 no. 20 1759-1767
DOI: 
https://doi.org/10.1212/01.wnl.0000435551.90824.d0
PubMed: 
24122185
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received January 8, 2013
  • Accepted in final form July 11, 2013
  • First Published October 11, 2013.

Article Versions

Copyright & Usage: 
© 2013 American Academy of Neurology

Author Disclosures

    1. Massimo Filippi, MD,
    2. Paolo Preziosa, MD,
    3. Massimiliano Copetti, PhD,
    4. Gianna Riccitelli, PhD,
    5. Mark A. Horsfield, PhD,
    6. Vittorio Martinelli, MD,
    7. Giancarlo Comi, MD and
    8. Maria A. Rocca, MD
  1. Massimo Filippi, MD,
    2. Scientific Advisory Boards:

    1. TEVA, Genmab

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Bayer-Schering, Biogen-Idec, Genmab, Merck-Serono, Teva

    Editorial Boards:

    1. Editor in CHief, Journal of Neurology. Editorial Board Member: AJNR, BMC Musculoskeletal Disorders, Clinical Neurology and Neurosurgery, Erciyes Medical Journal, Journal of Alzheimer's Disease, Journal of Neuroimaging, Journal of Neurovirology, Lancet Neurology, Magnetic Resonance Imaging, Multiple Sclerosis, Neurological Sciences

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Consultancies: Bayer-Schering, Biogen-Idec, Genmab, Merck-Serono, Novartis, Teva

    Speakers' Bureaus:

    1. Bayer-Schering, Biogen-Idec, Genmab, Merck-Serono, Teva.

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Grant/research support from: 1) Commercial entity: Bayer-Schering2) Commercial entity: Biogen-Idec3) Commercial entity: Genmab4) Commercial entity: Merck-Serono5) Commercial entity: Novartis6) Commercial entity: Teva

    Research Support, Government Entities:

    1. 1) Italian Ministry of Health; grant number: RF-2010-2313220; role: P.I.; duration: December 2012-November 2015

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1) Fondazione Italiana Sclerosi Multipla (FISM)2) CurePSP

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Paolo Preziosa, MD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Massimiliano Copetti, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Gianna Riccitelli, PhD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Mark A. Horsfield, PhD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. (1) Xinapse Systems Ltd

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Vittorio Martinelli, MD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Dr Martinelli has received travel supports and speaker fees for activities with Biogen Domp?, Merck/Serono, Bayer Schering, Teva and Sanofi Aventis.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Giancarlo Comi, MD and
    8. Scientific Advisory Boards:

    1. In the last two years, I have received personal compensation as a member of Scientific Advisory Boards from commercial entities: 1)Bayer Schering, 2) Merck Serono International, 3) TEVA Pharmaceutical Ind. Ltd., 4) Sanofi-Aventis, 5) Genzyme, 6) Novartis 7) Actelion

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. In the past two years I have received honoraria for speaking activities from 1) TEVA Pharmaceutical Ind. Ltd, 2) Sanofi-Aventis, 3) Genzyme, 4) Serono SymposiaInternational Foundation, 5) Biogen, 6) Merck Serono,7)Novartis, 8)Bayer Schering

    Editorial Boards:

    1. 1) Neurological Sciences, associate editor, 2011-2013

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. In the last two years, I have received personal compensation as a member of Scientific Advisory Boards from commercial entities: 1)Bayer Schering, 2) Merck Serono International, 3) TEVA Pharmaceutical Ind. Ltd., 4) Sanofi-Aventis, 5) Genzyme, 6) Novartis 7) Actelion

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Maria A. Rocca, MD
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Serves as consultant to Biogen idec and serono symposia

    Speakers' Bureaus:

    1. Received speaker honoraria from Biogen Idec and Serono Symposia International Foundation

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Italian Ministry of Health GR-2008-1138784, PI, from 2011 to 2013 GR-2009-1529671, PI, from 2012 to 2014 Fondazione Italiana Sclerosi Multipla, FISM 2012/R/15 2012-2014

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Neuroimaging Research Unit (M.F., P.P., G.R., M.A.R.), Institute of Experimental Neurology, and Department of Neurology (M.F., P.P., V.M., G.C., M.A.R.), San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan; Biostatistics Unit (M.C.), IRCCS-Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy; and Medical Physics Group (M.A.H.), Department of Cardiovascular Sciences, University of Leicester, Leicester Royal Infirmary, UK.
  1. Correspondence to Prof. Filippi: filippi.massimo{at}hsr.it
View Full Text

Article usage

Article usage: October 2013 to April 2023

AbstractFullPdfSource
Oct 2013615260Highwire
Nov 2013160014788Highwire
Dec 201330611934Highwire
Jan 20142004620Highwire
Feb 20141143422Highwire
Mar 2014731812Highwire
Apr 2014451911Highwire
May 201450279Highwire
Jun 201436145Highwire
Jul 20145867Highwire
Aug 20143122Highwire
Sep 20144056Highwire
Oct 20143064Highwire
Nov 201437139Highwire
Dec 20142633Highwire
Jan 20153345Highwire
Feb 201524125Highwire
Mar 201535149Highwire
Apr 20152032Highwire
May 20151698Highwire
Jun 20151184Highwire
Jul 20152711Highwire
Aug 201520164Highwire
Sep 201524136Highwire
Oct 20151563Highwire
Nov 20151721Highwire
Dec 20152345Highwire
Jan 20161244Highwire
Feb 20162777Highwire
Mar 20162478Highwire
Apr 20161453Highwire
May 20161421Highwire
Jun 20161143Highwire
Jul 2016900Highwire
Aug 20161352Highwire
Sep 2016711Highwire
Oct 20162422Highwire
Nov 20161512Highwire
Dec 20161621Highwire
Jan 20172123Highwire
Feb 2017820Highwire
Mar 20171033Highwire
Apr 20171402Highwire
May 20171301Highwire
Jun 2017211Highwire
Jul 2017601Highwire
Aug 2017711Highwire
Sep 20171053Highwire
Oct 2017500Highwire
Nov 20172010Highwire
Dec 20171210Highwire
Jan 20183153Highwire
Feb 20183932Highwire
Mar 2018510Highwire
Apr 20182500Highwire
May 20181870Highwire
Jun 20181682Highwire
Jul 20181422Highwire
Aug 20183674Highwire
Sep 2018141912Highwire
Oct 20183944Highwire
Nov 20182554Highwire
Dec 20181821Highwire
Jan 20192432Highwire
Feb 20191954Highwire
Mar 20191712Highwire
Apr 20191110Highwire
May 20191041Highwire
Jun 20191473Highwire
Jul 20191854Highwire
Aug 20192576Highwire
Sep 201916138Highwire
Oct 20194176Highwire
Nov 20192012Highwire
Dec 20192701Highwire
Jan 202027128Highwire
Feb 20203111Highwire
Mar 20202300Highwire
Apr 20202533Highwire
May 20202543Highwire
Jun 20202585Highwire
Jul 20201911Highwire
Aug 20202324Highwire
Sep 20203811Highwire
Oct 20202522Highwire
Nov 20202933Highwire
Dec 20202731Highwire
Jan 20213452Highwire
Feb 20214011Highwire
Mar 20213000Highwire
Apr 20212120Highwire
May 20211941Highwire
Jun 20212832Highwire
Jul 20213820Highwire
Aug 2021301913Highwire
Sep 20211810Highwire
Oct 20212823Highwire
Nov 20212462Highwire
Dec 20212922Highwire
Jan 20224835Highwire
Feb 20222623Highwire
Mar 20224321Highwire
Apr 20223711Highwire
May 20225010Highwire
Jun 20222442Highwire
Jul 20221423Highwire
Aug 20222034Highwire
Sep 20222043Highwire
Oct 20222811Highwire
Nov 20224643Highwire
Dec 20224122Highwire
Jan 20234541Highwire
Feb 20234043Highwire
Mar 20236862Highwire
Apr 20233410Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

More Online

CME Course

Topics Discussed

Alert Me

Recommended articles